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Abstract
Prions are the proteinaceous infectious agents responsible for Transmissible Spongiform Encephalopathies. Compelling
evidence supports the hypothesis that prions are composed exclusively of a misfolded version of the prion protein (PrP
Sc)
that replicates in the body in the absence of nucleic acids by inducing the misfolding of the cellular prion protein (PrP
C). The
most common form of human prion disease is sporadic, which appears to have its origin in a low frequency event of
spontaneous misfolding to generate the first PrP
Sc particle that then propagates as in the infectious form of the disease. The
main goal of this study was to mimic an early event in the etiology of sporadic disease by attempting de novo generation of
infectious PrP
Sc in vitro. For this purpose we analyzed in detail the possibility of spontaneous generation of PrP
Sc by the
protein misfolding cyclic amplification (PMCA) procedure. Under standard PMCA conditions, and taking precautions to
avoid cross-contamination, de novo generation of PrP
Sc was never observed, supporting the use of the technology for
diagnostic applications. However, we report that PMCA can be modified to generate PrP
Sc in the absence of pre-existing
PrP
Sc in different animal species at a low and variable rate. De novo generated PrP
Sc was infectious when inoculated into
wild type hamsters, producing a new disease phenotype with unique clinical, neuropathological and biochemical features.
Our results represent additional evidence in support of the prion hypothesis and provide a simple model to study the
mechanism of sporadic prion disease. The findings also suggest that prion diversity is not restricted to those currently
known, and that likely new forms of infectious protein foldings may be produced, resulting in novel disease phenotypes.
Citation: Barria MA, Mukherjee A, Gonzalez-Romero D, Morales R, Soto C (2009) De Novo Generation of Infectious Prions In Vitro Produces a New Disease
Phenotype. PLoS Pathog 5(5): e1000421. doi:10.1371/journal.ppat.1000421
Editor: David Westaway, University of Alberta, Canada
Received April 7, 2008; Accepted April 9, 2009; Published May 15, 2009
Copyright:  2009 Barria et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Institute of Neurological Disorders (R01 NS49173), the National Institute of Allergy and Infectious
Diseases (P01 AI77774) and the National Institute of Aging (P01 AG14359). None of the sponsors or funders played any role in the design and conduct of the
study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.
Competing Interests: Dr. Soto is an inventor on the PMCA technology and a Founder, Vice-President and Chief Scientific Officer of Amprion Inc, a biotech
company focusing on the development of early and sensitive diagnosis for prion diseases and other disorders involving protein misfolding.
* E-mail: claudio.soto@uth.tmc.edu
Introduction
Prions are the proteinaceous infectious agents responsible for
Transmissible Spongiform Encephalopathies (TSEs), a group of
fatal neurodegenerative disorders, including Creutzfeldt-Jakob
disease (CJD) in humans, scrapie in sheep, bovine spongiform
encephalopathy in cattle and chronic wasting disease in deer [1].
Compelling evidence support the hypothesis that the infectious
agent is composed exclusively by a misfolded version of the prion
protein (PrP
Sc) that replicates in the body in the absence of nucleic
acids by inducing the misfolding of the cellular prion protein
(PrP
C) [2]. Recent studies have reported in vitro generation of
infectious material by inducing or amplifying PrP misfolding,
providing strong support for the prion hypothesis [3–5].
In addition of the infectious origin, TSEs can be inherited or
appear sporadically. The latter is the most common origin in
humans, in which there are no known infectious source and no
evidence of the disease in the prior or subsequent generations of
the patient’s family. Sporadic CJD occurs worldwide with an
approximate frequency of 1 new case per million people each year
[1]. Molecularly, it is thought that sporadic TSEs arise from the
low frequency, spontaneous misfolding of the prion protein which
then propagates to other PrP
C molecules in a manner similar as in
the infectious cases.
Based on the knowledge of the molecular mechanism of prion
conversion, we have developed the PMCA (Protein Misfolding
Cyclic Amplification) technology, designed to mimic PrP
Sc
autocatalytic replication in vitro [6]. In a cyclic manner, minute
quantities of PrP
Sc (as little as one single particle) induce misfolding
of large amounts of PrP
C in a process catalyzed by ultrasound
waves to multiply the number of converting units. We and others
demonstrated that PrP
Sc can be maintained replicating in vitro
indefinitively [3,7]. More importantly, inoculation of in vitro
generated PrP
Sc produced disease in wild type animals [3]. The
newly generated protein exhibits the same biochemical, biological,
and structural properties as brain-derived PrP
Sc and maintains the
species-barrier and strain-specific characteristics [8–10]. These
findings represent one of the strongest evidences in favor of the
prion hypothesis. However, since infectious material was gener-
ated using crude brain homogenates as substrate and starting from
small amounts of brain derived infectivity, we cannot absolutely
rule out that another agent besides of PrP
Sc was replicated during
the PMCA process. In this sense a great advance was reported by
Supattapone and co-workers with the in vitro generation of PrP
Sc
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C and PrP
Sc with the
sole addition of a synthetic polyanion [4]. Moreover, these authors
described that misfolded and infectious protein was generated de
novo, in hamsters under conditions in which the possibility of cross-
contamination was greatly reduced. The result was a hamster
strain very similar to the commonly used 263K hamster strain [4].
Spontaneous generation of PrP
Sc and infectivity was also described
in an experiment in which a recombinant mouse PrP fragment
(residues 89–230) assembled into amyloid fibrils was found to
induce a TSE-like disease with PrP
Sc formation when injected in
transgenic mice overexpressing the same PrP sequence [5].
Although these findings are very interesting, the fact that the
disease was transmitted in a first passage only to transgenic
animals largely over-expressing the PrP gene and not to wild-type
animals is a matter of concern. It is well known that this type of
animals develop spontaneously a prion-like disease at advanced
age [11–13]. In other words, the effect seen might just be an
acceleration of the disease process that was set to occur
spontaneously at a later time [14].
The main goal of the current study was to identify conditions
which permit the de novo generation of PrP and infectivity using
PMCA in brain homogenates. Our hypothesis was that if sporadic
prion disease originates from a low frequency process of
spontaneous PrP
C misfolding, we should be able to pick up and
propagate this event using PMCA. However, in our experience
thousands PMCA experiments have only rarely shown PrP
Sc
formation in control samples without infectious material and in
these extremely uncommon cases we could not rule out the
possibility of cross-contamination.
Results
To assess more systematically the putative de novo formation of
PrP
Sc in vitro, we performed 20 serial rounds of PMCA using 10
different mouse and hamster uninfected brains. For this experi-
ment we used the standard PMCA conditions, in which each
round consists of 144 cycles of 30 minutes incubation followed by
a 20 s pulse of sonication. To minimize the possibility of cross-
contamination, the experiment was done in a room that has never
been exposed to prions and using all new equipment and reagents.
Half of the samples were also incubated in the presence of poly-A
oligonucleotide, a synthetic polyanion which have been shown to
promote PrP
Sc formation in vitro by PMCA [4,15]. The result of
this experiment did not show protease-resistant PrP in any of the
conditions tested neither in mouse (Fig. 1A) nor in hamster
(Fig. 1B) samples. The efficiency of the equipment and reagents
used to replicate prions was confirmed thereafter in an experiment
in which standard PMCA was done to amplify diverse quantities of
brain-derived mouse or hamster PrP
Sc (Fig. 1C and D). These
results indicate that under standard PMCA conditions in which
cross-contamination has been avoided, spontaneous formation of
hamster or mouse PrP
Sc does not occur.
We reasoned that replication starting with a spontaneously
formed and unstable intermediate of PrP
Sc, as the expected
precursor of sporadic disease, may require different conditions to
propagatethanamature,stablePrP
Scform.Thus,tofurtherattempt
de novo generation of PrP
Sc we tested various changes of the PMCA
conditions (see below). In particular we assessed whether longer
incubation periods before dilution in a second round may benefit
amplification of de novo generated prions. We also tested whether
human brain material may have a greater propensity to produce
PrP
Sc spontaneously, because of the known incidence of sporadic
disease in the population [16]. After several, extended serial rounds
of PMCA, consisting of 240 PMCA cycles (5 days of sonications
every 30 min each), we observed a protease-resistant PrP band
similar to PrP
Sc in hamsters and mice, but not in humans or
transgenic mice over-expressing human PrP (Fig. 2). Interestingly,
the rate of spontaneous formation as well as the number of PMCA
rounds needed to generate de novo PrP
Sc was different in distinct
species. Only 1 out of 10 samples of hamsters and mice gave a PrP
Sc
signal, which appeared after 9 and 10 rounds of PMCA, respectively
(Fig. 2A and C). With human material we never observed
spontaneous formation of PrP
Sc. The variable rate of spontaneous
generation of PrP
Sc in different species argues against the possibility
of cross-contamination as the source of de novo PrP
Sc. To further rule
out contamination, the entire experiment was repeated in a prion-
free room with all new equipment and reagents. Under these
conditions we observed a very similar rate of spontaneous
appearance of PrP
Sc in different species (Fig. 2B). Again human
materialdid not showsignal and hamstersand miceshowed low,but
detectable levels of PrP
Sc spontaneous appearance (20% and 10%,
respectively). The PMCA rounds in which the first PrP
res signals
appeared was also similar in both experiments (Fig. 2C). The
efficiency of PrP
C from human and humanized transgenic mice
brain to undergo conversion into PrP
Sc by PMCA was checked by
performing a standard seeded PMCA experiment. As shown in Fig.
S1, these substrates supported prion replication. At this time we do
not know whether PMCA replicated a PrP
Sc intermediate already
present inthebrain homogenate orrather ‘‘spontaneous’’ misfolding
was induced during PMCA. In order to gain insight regarding this
issue, we subjected the samples of normal brain homogenate to
conditions that could increase misfolding, such as heating at 55uC,
addition of detergents (SDS or digitonin) and changes in pH
(pH 5.0). To attempt stabilizing a pre-formed intermediate, we pre-
incubated with shaking the normal brain homogenate for 24 h prior
PMCA. None of these conditions resulted in detectable de novo
formation of PrP
Sc in healthy brain homogenate from hamsters (Fig.
S2) or human transgenic mice (Fig. S3).
To assess whether de novo PrP
Sc is infectious, we injected intra-
cerebrally the protein generated using hamster brain homogenate
(lane 6 in Fig. 2A) into wild type animals. Simultaneously, we
inoculated groups of hamsters with similar quantities of PrP
Sc
obtained from the brain of animals injected with three well-
characterized hamster prion strains: 263K, Hyper (HY) and Drowsy
(DY) [17,18]. All animals inoculated with de novo generated PrP
Sc
showed clear behavioral abnormalities, including tremor of the
head, wobbling gait, head bobbing and reduced or absent
Author Summary
Prions are the unprecedented infectious agent associated
with prion diseases, which are composed exclusively of a
misfolded protein. In this study we report the de novo
formation of infectious prion protein in vitro, which when
inoculated into wild type animals is able to induce a new
disease phenotype with unique clinical, neuropathological
and biochemical characteristics. The findings described in
this article are very important, because they support the
prion hypothesis and provide a simple model for studying
the mechanism responsible for the appearance of sporadic
prion disease. The data also suggest that the universe of
possible prions is not restricted to those currently known,
but that likely many new forms of infectious protein
foldings may be produced. This is worrisome, because it
raises the possibility that novel and perhaps more
aggressive infectious prion foldings may spontaneously
originate in diverse species, leading to the emergence of
new and unpredictable forms of transmissible diseases.
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tivity and aggressiveness that are typical of the most common
hamster prion strains (such as 263K, Sc237 and HY). The disease
progressed quickly, resulting in death between 2–3 weeks after the
appearance of the first clinical signs. The average incubation period
for the animals inoculated with de novo produced PrP
Sc, termed
PMCA-generated prions in hamsters (PGP-h1), was 112.665.2
days, which was statistically significantly different from the
incubation times obtained for 263K (89.861.1 days), HY
(86.560.65 days) or DY (218.862.1 days) (Fig. 3A). We are
currently doing serial passages and end-point titration of this new
infectious material to investigate its stability and infectivity titer. To
further analyze the characteristics of the disease produced by in vitro
generated PrP
Sc we performed behavioral experiments using an
open field test. Three different parameters were measured, including
distance traveled in a 20 s period (Fig. 3B), vertical activity (Fig. 3C)
andpercentageoftimeinwhichanimalsremainedinactive(Fig.3D).
Animals inoculated with PGP-h1 showed substantially less traveling
activity than the hyperactive 263K sick animals, but significantly
higher than the lethargic DY hamsters (Fig. 3B). The distance
traveled was not substantially different than control uninoculated
hamsters, but the PGP-h1 animals have a substantially reduced
vertical activity (Fig. 3C) and a much higher rate of inactive time
(Fig. 3D) than healthy hamsters. The disease observed in de novo
inoculated animalsdiffered fromthe two hamster strains studied also
in the percentage of inactive time, which was greater than in 263K
but lower than in DY (Fig. 3D). The reduced horizontal and vertical
activity and increased inactive time in PGP-h1 sick hamsters
compared to healthy animals could be interpreted as increased
anxiety or fear, but this is unlikely since similar behavior was
observed when the experiment was repeated in the home cage. The
abnormal behavior is probably reflecting a social withdrawal and
lack of exploratory interest. These findings indicate that the clinical
characteristics of the disease produced by inoculation of PGP-h1
PrP
Sc are different from the symptoms observed in typical hamster
strains, which is also evident by simply observing video recording of
these animals (see Video S1 and Video S2 in supporting online
material).
Figure 1. Standard PMCA does not lead to spontaneous generation of PrP
Sc. Ten different mouse (A) and hamster (B) brain samples were
subjected to serial rounds of PMCA in the absence of PrP
Sc inoculum. A total of 20 rounds of 144 PMCA cycles were done and after each round the
appearance of PrP
res after PK digestion was tested by western blot. The figure shows the results obtained in passages 6, 10, 16 and 20, and 5
representative samples of the 10 analyzed. In half of the samples, the PMCA reaction was done in the absence and the other half in the presence of
20 mg/ml synthetic poly-A oligonucleotide. These studies were done in a prion-free room using all new equipment and reagents. In some lanes
(labeled with an asterisk) it is possible to appreciate a very faint band with the same molecular weight as PrP
C, which is the result of incomplete
digestion with PK. The efficiency of PMCA using these conditions was tested by running standard PMCA experiments using different dilutions of
infected mouse (C) or hamster (D) brain homogenate. The experiment was done using 144 PMCA cycles and the results showed a robust
amplification of the signal as previously described [21,34]. All samples were digested with PK before western blot, except in the normal brain
homogenate (NBH), used as control of PrP
C migration. MBH: healthy mouse brain homogenate; HBH: healthy hamster brain homogenate; F: frozen
samples; A: amplified samples.
doi:10.1371/journal.ppat.1000421.g001
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showed neuropathological alterations typical of prion disease,
including spongiform degeneration, astroglyosis and PrP accumu-
lation (Fig. 4). Extensive vacuolation was observed in medulla and
colliculus, whereas the extent of spongiosis was smaller, but
detectable, in hippocampus and cerebellum and almost non-existent
in cortex (Fig. 4A). Hippocampal spongiosis was mostly detected in
areasoftheCA1regionratherthaninthedentategyruslayerswhere
vacuoles are frequently observed in other hamster strains.
Interestingly, comparison of the vacuolation profile in distinct brain
areas with those observed inhamstersaffected byother prion strains,
showed that the neuropathological pattern of PGP-h1 is clearly and
significantly different from all the others (Fig. 4B). The main
difference with the previously known strains is the substantial
spongiosis in colliculus and the lack of severe damage in cerebellum.
PrP
Sc diffuse deposits were observed in diverse areas of the brain
(Fig. 4C) and a protease-resistant misfolded protein was readily
detectable by western blot (Fig. 5A). The quantity of PrP
Sc was
similar to that observed in 263K infected animals, and was
substantially higher than in HY and DY sick hamsters. The
glycosylation profile of PGP-h1 PrP
Sc is undistinguishable from that
of other hamster strains and is dominated by the di-glycosylated
band (Fig. 5A). The electrophoretic mobility was assessed by western
blot after PK treatment and de-glycosylation with PNGase enzyme.
Under these conditions PGP-h1 PrP
Sc showed an approximate
molecular weight of 21 kDa, not different from 263K or HY PrP
Sc,
Figure 2. De novo generation of PrP
Sc in diverse animal species. (A) Samples from 10 different healthy brain homogenates from human,
hamster, mouse or humanized transgenic mice were subjected to successive rounds of extended PMCA. Each round consisted of 240 PMCA cycles
(30 min incubation followed by a 20 s pulse of sonication). Aliquots of each sample were treated with PK and analyzed by western blot. The results of
rounds 3, 6, 9 and 10 are shown. (B) The same experiment as in A was repeated in a prion-free laboratory with all new equipment and reagents to
reduce the possibility of cross-contamination. Only the round 10 is shown, but overall the results are very similar as those described in panel A. All
samples were digested with PK before Western blot, except in the normal brain homogenate (NBH), used as control of PrP
C migration. (C) Rate of
spontaneous generation of protease-resistant PrP (PrP
res) in different species at each of the PMCA rounds performed. Full bars represent the results
obtained in the experiment conducted in our standard facility (as shown in panel A) and empty bars the experiment done in prion-free room with all
new equipment and reagents (as shown in panel B).
doi:10.1371/journal.ppat.1000421.g002
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Sc
(Fig. 5B). Another important biochemical difference among PrP
Sc
from different strains is the degree of resistance to proteolytic
degradation [19]. To measure this, we subjected similar quantities of
PrP
Sc from diverse strains to increasing PK concentrations. As
shown in Fig. 5C, PrP
Sc associated with de novo generated prions has
a significantly lower resistance to proteolysis relative to the misfolded
protein from other hamster strains. The PK50 value (which
represents the protease concentration in which 50% of PrP
Sc is
eliminated), for PGP-h1 was 623 ug/ml, compared to 1782, 1265
and 926 for 263K, HY and DY PrP
Sc, respectively (Fig. 5C).
Discussion
In this study we report spontaneous generation of PrP
Sc in vitro
using a modified PMCA procedure with brain homogenate
substrate. Misfolded protein was produced in two different animal
species without the need to add seeds of in vivo generated PrP
Sc.A t
present it is unclear whether PMCA replicated a PrP
Sc
intermediate already present in the brain homogenate or rather
‘‘spontaneous’’ misfolding was induced by the amplification cycles.
In this context, a recent study reported the presence of small
quantities of a PrP
Sc-like protein in healthy brains [20], but it is yet
unknown whether this protein is infectious.
Although de novo prion formation was achieved before by
PMCA using purified proteins in the presence of synthetic
polyanions [4], the purpose of our study was to evaluate whether
de novo generation of prions is possible under standard PMCA
conditions. This is important to assess the validity of using PMCA
for prion diagnosis. Another aim was to study whether different
species of animals have a distinct propensity to form spontaneous
prions under a given set of conditions. Finally, we aimed to
characterize the newly generated infectivity and to show that the
diversity of prions is perhaps larger than we currently think. Our
results indicate that standard PMCA rounds consisting of 144
cycles (or less) did not show spontaneous formation of PrP
Sc, but
Figure 3. De novo generated PrP
Sc is infectious, producing a new clinical disease. (A) Groups of 5 hamsters were intra-cerebrally (i.c.)
inoculated with similar quantities of PrP
Sc from either de novo generated protein (PGP-h1) or three well-established hamster prion strains, including
263K, HY and DY. Clinical signs were monitored weekly as described in Materials and Methods and when the signs progressed up to the level 4 of our
scale, animals were considered sick and sacrificed to avoid excessive pain. This time is recorded as incubation period and is represented in the figure
as days post-inoculation (d.p.i.). Differences on the incubation periods produced by the diverse sources of infectious material were analyzed by one-
way ANOVA and were found highly significant (P,0.001). The significance of the differences between PGP-h1 and each of the other hamster prion
strains were evaluated by the Dunnett Multiple Comparison post test. All differences were statistically significant (P,0.001). Behavioral alterations
during the clinical phase of the disease in animals inoculated with various prion strains were assessed by an open field test, as described in Materials
and Methods. Hamsters at mid stages of the disease (around 1 week after the first clinical signs were observed) were placed in a corner of the field
and its behavior recorded for five minutes. We measured and analyzed total distance traveled during 20 s intervals (B), time that animals spent in
vertical activity (C) and inactive time (D). The last two parameters are represented as a percentage of the total time. Tests were done twice for each
animal and the result showed in the figure correspond to the average of the two determinations. Behavioral data was analyzed by one-way ANOVA
with the Dunnett multiple comparison post-test. Statistical probability that the differences between PGP-h1 and control animals or hamsters
inoculated with the other strains are different is indicated in the figure.
doi:10.1371/journal.ppat.1000421.g003
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generating misfolded protein. These findings suggest that de novo
formation of PrP
Sc can be experimentally distinguished from
replication of pre-formed PrP
Sc, indicating that the biochemical,
conformational or stability properties of the PrP structures
involved in both processes are probably different. Therefore,
PMCA can be adapted to produce de novo generated PrP
Sc and it is
likely that more drastic modifications of the procedure may lead to
higher rates of spontaneous prion formation. Indeed, the higher
rate of de novo PrP
Sc formation reported in the study by Deleault
and colleagues, who used only 48 PMCA cycles per round [4],
indicates that using polyanions and purified PrP
C may favor
spontaneous prion formation, suggesting that some factors in brain
homogenate may prevent PrP misfolding.
Our data support the use of PMCA, (under conditions in which
PrP
Sc de novo generation does not occur), for biochemical detection
of prions and its potential application for TSE diagnosis. The
usefulness of PMCA for highly sensitive and specific detection of
prions in biological fluids, has been demonstrated by studies from
us and other groups [21–25].
Strikingly, the rate and number of PMCA cycles required to
produce de novo PrP
Sc was variable in distinct species. Considering
that from the species studied humans are the only one in which
sporadic disease is known to occur, we were surprised that de novo
PrP
Sc was never obtained with human brain homogenates under
the experimental conditions used. This contrast with the high
levels of amplification of human PrP
Sc observed in samples seeded
with vCJD (Fig. S1) or various sCJD brain homogenates (data not
shown). The absence of spontaneous formation of PrP
res in
humans may be due to the different conditions for the preparation
of the tissue, including several hours of post-mortem delay or the
lack of perfusion before collection of the brain. However, this is
unlikely, because similar results were obtained using brains of
transgenic mice expressing human PrP subjected to the same
conditions to prepare brain than the other rodent species. Our
interpretation of these results is that human PrP
C has a lower
Figure 4. Histopathological brain damage in hamsters inoculated with de novo generated prions. (A) Five different brain areas of animals
sacrificed with clinical signs of disease induced by PGP-h1 infection and un-inoculated age-matched controls were analyzed histologically for
spongiform degeneration after hematoxilin-eosin staining. (B) The vacuolation profile in each brain area was estimated using a semi-quantitative
scale, as described in Materials and Methods. We also included in the analysis brain sections from animals inoculated with the other hamster prion
strains studied. The values represent the average6standard error of the extent of vacuolation from the 5 animals analyzed in each set. Statistical
analysis by two-ways ANOVA, using brain regions and prion origin as the variables indicated that differences were highly significant (P,0.001). To
assess the significance of the differences between each known prion strain and PGP-h1, we used the Dunnett multiple comparison post-test and the
P values for each combination are shown in the figure. (C) PrP
Sc accumulation and astroglyosis were studied by immunohistochemistry using anti-PrP
and anti-GFAP antibodies, respectively. In the figure we show the staining in medulla as a representative brain region where substantial damage was
observed. Staining of the brain of un-inoculated animals was included as a negative control.
doi:10.1371/journal.ppat.1000421.g004
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alternative explanation that factors present in the human brain
may prevent conversion is unlikely considering the experiments
with humanized transgenic mice. The appearance of sporadic
disease in humans may simply reflect the longer life span that
provides greater chances for stochastic processes of spontaneous
misfolding. However, it is also possible that sporadic disease is
actually more frequent in animals, because the rate of spontaneous
illness in animals has not been systematically studied.
Several lines of evidence enable us to rule out the possibility that
de novo PrP
Sc was the result of cross-contamination. First of all,
conventional PMCA that allows us to amplify as little as a single
particle of PrP
Sc did not show spontaneous formation of misfolded
protein, even after extensive PMCA cycling (Fig. 1). Second, the
rate of spontaneous generation of prions in different species does
not correlate with the availability of infectious material in our lab.
Moreover, the variable rate was surprisingly constant among
different experiments, arguing that it is dependent on some
intrinsic properties of the protein rather than a stochastic event as
cross-contamination. Third, an experiment done using strictly
prion-free equipment and reagents, performed in a new laboratory
that was never exposed to prions and done by a person who has
never been in contact with prion material showed very similar
results as the one carried out in our standard facilities. Finally, the
biochemical, structural and biological properties of de novo
generated PrP
Sc in hamster were substantially different to those
of various conventional hamster prion strains. Although all these
evidences strongly indicate that the results are not due to cross-
contamination, this possibility cannot entirely be ruled out.
Inoculation of wild type hamsters with de novo generated PrP
Sc
produced disease in all animals. Strikingly, many of the disease
characteristics were substantially different to those observed with
several other hamster prion strains. In this study we directly
compared PGP-h1 with 3 well-established strains (263K, HY and
DY) and literature comparisons with other strains such as Sc237,
SHa(Me7), MT-C5, SHa(RML), 139H and Me7-H, also show
Figure 5. Biochemical characteristics of PrP
Sc obtained in animals infected with de novo generated prions. (A) To estimate the relative
quantity of PrP
Sc in the brain of animals inoculated with different prion strains, the tissue was homogenized and aliquots corresponding to a 10-, 50-,
and 1000-fold dilutions (respect to the entire brain) were analyzed by western blot after PK treatment. (B) The size of the PK-resistant fragment in
each strain was assessed by western blot after treatment with the protease and deglycosylated as described in Materials and Methods. (C) The
relative sensitivity of PGP-h1 PrP
Sc to proteolytic degradation was studied and compared with that of PrP
Sc associated to other hamster strains. For
this study, aliquots of brain homogenate were incubated for 60 min at 37uC with the indicated concentrations of PK and PrP
Sc signal remaining was
detected by Western blot. All samples were digested with PK before Western blot, except in the normal brain homogenate (NBH), used as control of
PrP
C migration. (D) Densitometric analysis of the western blots of 3 independent experiments as the one shown in the panel C was done to calculate
the quantity of PrP
Sc digested with each PK concentration. This data enable to determine the susceptibility of PrP
Sc from the various sources to PK
digestion and to estimate the PK50 value, which corresponds to the PK concentration needed to degrade 50% of the protein. The PK50 values
(expressed in ug/ml of the protease) for each strain are indicated at the bottom of panel C. The data represent the average6standard error. The data
was analyzed by two ways ANOVA (with source of the materials and PK concentration as the variables) and the Dunnett multiple comparison post-
test. Each set of data was compared to the results obtained with the PGP-h1 strain and significant differences are highlighted with asterisks
(*=P,0.05; **=P,0.01; ***=P,0.001).
doi:10.1371/journal.ppat.1000421.g005
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amplification of PrP
Sc from various strains (of hamsters, mice,
human or deer origin) faithfully propagates the strain character-
istics [8–10,28,29]. Thus, the differences observed in the de novo
generated material are not attributable to PMCA amplification,
but to intrinsic differences of this new prion strain. In our direct
comparisons the incubation time of PGP-h1 was significantly
larger than 263K and HY strains, but much shorter than DY.
Clinical signs were also clearly distinguishable from those observed
in animals affected by other strains (see Video S1 and Video S2 in
supporting online material). The animals inoculated with PGP-h1
were not hyperactive or aggressive, but not lethargic either. They
exhibited a social withdrawal and lack of interest for the
surroundings, which reflected in a much reduced horizontal and
vertical activity and increased extent of inactive time in an open
field test. The clinical differences on the PGP-h1 induced disease
were likely the result of the severe brain damage produced,
including extensive spongiform degeneration, PrP
Sc accumulation
and brain inflammation. Remarkably, the brain areas targeted by
vacuolation damage were significantly different from all other
hamster strains studied and included a substantially greater extent
of spongiosis in colliculus and a much reduced level of injury in
cerebellum and cortex. The biochemical characteristics of PrP
Sc
were also different in PGP-h1, mostly in terms of the higher
quantity of PrP
Sc accumulated in the brain and the lower relative
resistance to proteolytic degradation than the other hamster strains
analyzed. Taken together this data demonstrate that de novo
generated prions correspond to a novel strain of infectious
material, able to generate a new disease in wild type animals.
We are currently assessing the infectious properties of some of the
other de novo generated PrP
Sc obtained in this study to examine
whether or not new strains and new diseases are produced also in
other species.
Our findings provide a model to study the possible origins of
sporadic TSEs and a new avenue to investigate the mechanism
and factors controlling spontaneous formation of infectious
material. For example, using the modified PMCA reaction
described in this study we could assess the sequence determinants
of the variable propensity of PrP
C in distinct species to undergo
conversion into the pathological form. We could also study the
contribution of other factors in brain to alter the rate of de novo
generation of PrP
Sc. Finally, our data provides further support for
the prion hypothesis, since misfolded and infectious protein was
generated in vitro, without the need for addition of pre-existing
PrP
Sc. The fact that the de novo generated PrP
Sc corresponds to a
new strain of infectious material suggest that the diversity of
alternative and transmissible foldings that PrP
Sc can adopt is much
larger than usually thought. This is worrisome, because it raises
the possibility that novel and perhaps more aggressive infectious
prion foldings may spontaneously originate in diverse species,
leading to the emergence of new and unpredictable forms of
transmissible diseases.
Materials and Methods
Preparation of brain homogenates
Brains from different healthy hamsters, wild type mice, and
Tg35 transgenic mice over-expressing human PrP (MM genotype)
[30] were extracted after animals were perfused with phosphate-
buffered saline (PBS) plus 5 mM EDTA. The human brain used
for these studies corresponded to a piece of cortex from a young
person (MM phenotype at codon 129) who died from non-
neurological disease. The post-mortem delay was 3.5 h. Wild type
mice and hamsters were purchased from Jackson laboratory, the
human transgenic mice were breaded in our facility and human
frozen brain was kindly donated by Dr Pierluigi Gambetti. Ten
percent brain homogenates (w/v) were prepared in conversion
buffer (PBS containing NaCl 150 mM, 1.0% Triton X-100, 4 mM
EDTA and the complete
TM cocktail of protease inhibitors from
Boehringer Mannheim, Mannheim, Germany).
PMCA procedure
Aliquots of 100 ul of 10% healthy brain homogenate were
loaded onto 0.2-ml PCR tubes. Tubes were positioned on an
adaptor placed on the plate holder of a microsonicator (Misonix
Model 3000, Farmingdale, NY) and programmed to perform
cycles of 30 min incubation at 37uC followed by a 20 s pulse of
sonication set at potency of 7. Samples were incubated without
shaking immersed in the water of the sonicator bath. Standard
PMCA rounds consisted of 144 cycles, whereas extended PMCA
consisted of 240 cycles. After each round of cycles, a 10 ul aliquot
of the amplified material was diluted into 90 ul of normal brain
homogenate and a new round of PMCA cycles was performed.
The detailed protocol for PMCA, including reagents, solutions and
troubleshooting, has been published elsewhere [31–33]. Some of
the measures used to minimize cross-contamination were the
following: the experiments were done in a laminar flow biosafety
cabinet, using disposable materials and aerosol barrier tips. The
experimenter was wearing disposable coats, shoe, head and mouth
covers and double pair of gloves. All tubes were spin down before
opening after any procedure. We avoided spills, clean frequently
bench, pipettes and other materials with NaOH, change water and
clean sonicator cup with NaOH after each experiment and do not
mix prions from different sources in one sonicator. As described in
the text, some experiments were carried out entirely in a different
laboratory that had never been exposed to prions, using all new
reagents, equipment and conducted by an operator who has not
been exposed to the prion laboratory.
Proteinase K degradation assay
The standard procedure to digest PrP
Sc consists on subjecting
the samples to incubation in the presence of PK (50 mg/ml) during
60 min with shaking at 37uC. The digestion was stopped by
adding electrophoresis sample buffer and the protease-resistant
PrP was revealed by western blotting, as indicated below. To study
the profile of PK sensitivity for de novo generated PrP
Sc, the samples
were incubated for 60 min at 37uC with different concentrations
of PK ranging from 150 to 1500 mg/ml.
Western blot
Proteins were fractionated by sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE), electroblotted
onto nitrocellulose membrane and probed with 6D11 antibody at
a 1:5,000 dilution. The immunoreactive bands were visualized by
enhanced chemoluminesence assay (Amersham, Piscataway, NJ)
using a UVP image analysis system.
Protein deglycosylation assay
PrP
Sc samples were first digested with PK as describe above.
After addition of 10% sarkosyl, samples were centrifuged at
100,0006g for 1 h at 4uC, supernatant was discarded and pellet
resuspended in 100 ml of glycoprotein denaturing buffer (New
England Biolabs, Beverly, MA) and incubated for 10 min at
100uC. Thereafter, 13 ml of 50 mM sodium phosphate, pH 7.5
containing 1% nonidet P-40 and 3 ml of peptide N-glycosidase F
(New England Biolabs, Beverly, MA) were added. Samples were
incubated overnight at 37uC with shaking and the reaction was
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Western blot as indicated before.
PrP
Sc quantification
To inject the same quantity of PrP
Sc from each strain
preparation, the samples were compared by Western blotting
after PK digestion. To obtain a reliable and robust quantification,
we ran several different dilutions of the sample in the same gel, to
avoid artifacts due to saturation of the signal or to a too weak
signal.
Infectivity studies
In vivo infectivity studies were done in Syrian Golden female
hamsters, purchased from Charles River. Animals were 4- to 6-
weeks old at the time of inoculation. Anesthesized animals were
injected stereotaxically in the right hyppocampus with 2 ml of the
sample. The onset of clinical disease was measured by scoring the
animals twice a week using the following scale: 1, Normal animal; 2,
Mild behavioral abnormalities including tremor of the head and
wobbling gait; 3, Moderate behavioral problems including ataxia,
head bobbing and irritability; 4, Severe behavioral abnormalities
including all of the above plus jerks of the head and body and
spontaneous backrolls; 5, Terminal stage of the disease in which the
animal lies in the cage and is no longer able to stand up. Animals
scoring level 4 were considered sick and sacrificed to avoid excessive
pain using exposition to carbonic dioxide. Brains were extracted
and analyzed histologically. The right cerebral hemisphere was
frozenand stored at270uC forbiochemical studies ofPrP
Sc and the
left hemisphere was used for histology analysis.
Open field behavioral test
Hamsters at mid stages of the disease (around 1 week after the
first clinical signs were observed) were placed in a corner of the
field box and its behavior recorded for five minutes. All activity
was recorded by a video camera mounted above the open field
and scored in real-time. We measured and analyzed total distance,
average speed, time spent in various parts of the field, vertical and
horizontal activity and inactive time. Testing was carried out in a
temperature, noise and light controlled room.
Histopathological studies
Brain tissue was fixed in 10% formaldehyde solution, embedded
in paraffin and cut in sections. Serial sections (6 mm thick) from
each block were stained with hematoxylin-eosin, or incubated with
the 3F4 monoclonal antibody recognizing PrP or the glial fibrillary
acidic protein, using our previously described protocols [3].
Immunoreactions were developed using the peroxidase-antiper-
oxidase method, following manufacturer’s specifications. Antibody
specificity was verified by absorption. Samples were visualized
with a Zeiss microscope. The vacuolation profile was estimated by
considering both number and size of vacuoles. Each analyzed
brain area was scored from 0 to 4 according to the extent of
vacuolation in slides stained with haematoxilin-eosin and visual-
ized at a 406 magnification. Samples were analyzed blindly by
two different persons and the scores represent the average of the
two determinations.
Statistical analysis
The differences in incubation periods, behavioral analysis and
histopathoogical profile of brain damage were analyzed by one-
way ANOVA, followed by the Dunnett Multiple Comparison
post-test to estimate the significance of the differences between
PGP-h1 and each of the other hamster prion strains studied. For
these studies the data was analyzed using the GraphPad Instat,
version 3.05 software.
Supporting Information
Figure S1 Seeded amplification of diverse healthy brain samples
used in this study. To make sure that the healthy brain
homogenates used in this study were able to sustain prion
replication, different dilutions of vCJD brain homogenates were
diluted in 10% brain homogenates of healthy human, MM
genotype (Panel A) or humanized transgenic mice, MM genotype
(Panel B). All samples were subjected to 144 PMCA cycles. In
panel A, frozen (F) and amplified (A) samples are showed next to
each other for each dilution, whereas in panels B, frozen samples
are showed in the left gels and amplified samples in the right gels.
All samples were treated with PK before electrophoresis except
when indicated. The capacity of hamster and mouse samples to
sustain seeded prion replication is shown in Figure 1C and D of
the main text.
Found at: doi:10.1371/journal.ppat.1000421.s001 (2.71 MB TIF)
Figure S2 Lack of de novo formation of PrP
Sc in humanized
transgenic mice brain homogenate under various conditions. To
attempt increasing the rate of spontaneous formation of de novo
PrP
Sc we subjected the samples of 10% healthy transgenic mice
brain homogenates containing human (MM) PrP to various
alternative conditions, including: 1. heating the samples at 55uC
for 20 min prior to the first round of PMCA; 2. addition of 0.05%
digitonin to the conversion buffer; 3. addition of 0.1% SDS to the
conversion buffer; 4. changing the pH of the conversion buffer to
5.0; 5. pre-incubation of the brain homogenate under vigorous
shaking for 24 h at 37uC. Samples were subjected to serial rounds
of 144 PMCA cycles. Thereafter samples were treated with PK
and subjected to western blot. The figure shows the results of
rounds 3, 6, 9 and 10. No signal was observed in any of the other
rounds.
Found at: doi:10.1371/journal.ppat.1000421.s002 (4.40 MB TIF)
Figure S3 Lack of de novo formation of PrP
Sc in hamster brain
homogenate under various conditions. To attempt increasing the
rate of spontaneous formation of de novo PrP
Sc we subjected the
samples of 10% healthy hamster brain homogenates to various
alternative conditions, including: 1. heating the samples at 55uC
for 20 min prior to the first round of PMCA; 2. addition of 0.05%
digitonin to the conversion buffer; 3. addition of 0.1% SDS to the
conversion buffer; 4. changing the pH of the conversion buffer to
5.0; 5. pre-incubation of the brain homogenate under vigorous
shaking for 24 h at 37uC. Samples were subjected to serial rounds
of 144 PMCA cycles. Thereafter samples were treated with PK
and subjected to western blot. The figure shows the results of
rounds 3, 6, 9 and 10. No signal was observed in any of the other
rounds.
Found at: doi:10.1371/journal.ppat.1000421.s003 (3.72 MB TIF)
Video S1 Shows the behavior of hamsters affected by diverse
TSE prion strains as well as a control un-infected animal (right
box). One animal representative of the disease produced by
infection with 263K (center-right box), PGP-h1 (center left box)
and DY (left box) is shown. The typical hyperactive behavior of
the 263K sick animal, which is constantly moving in the cage,
contrast with the complete lethargic posture of the DY sick animal.
The PGP-h1 animal has an intermediate behavior, characterized
by lack of vertical activity, exploratory interest and substantial
inactive time, contrasting with the uninfected animal which is
mostly engaged on vertical exploration attempting to escape.
Found at: doi:10.1371/journal.ppat.1000421.s004 (7.17 MB AVI)
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animals. First, a hamster with clinical signs of the disease produced
by PGP-h1 inoculation. Animal exhibit rough coat and clear
motor problems including tremor of the head, wobbling gait, head
bobbing. It also show a much reduced exploratory behavior and
lack of interest for interacting with the object introduced in the
cage. The second animal corresponds to a 263K sick hamster
exhibiting the typical hyperactivity, motor impairments and
aggressiveness. Finally for comparison purposes we show the
behavior of a normal healthy hamster of similar age.
Found at: doi:10.1371/journal.ppat.1000421.s005 (7.69 MB AVI)
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